Wolfe Research Begins Coverage on Pharvaris (NASDAQ:PHVS)

Investment analysts at Wolfe Research assumed coverage on shares of Pharvaris (NASDAQ:PHVS) in a report released on Thursday. The brokerage set an “outperform” rating and a $42.00 price target on the stock. Wolfe Research’s target price would indicate a potential upside of 52.39% from the stock’s current price.

Several other equities analysts have also weighed in on PHVS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of Pharvaris from a “hold” rating to a “sell” rating in a research note on Sunday. Royal Bank Of Canada cut their price target on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Pharvaris in a research report on Tuesday, March 3rd. Finally, Wedbush raised their target price on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Pharvaris presently has an average rating of “Moderate Buy” and an average price target of $42.73.

Pharvaris Price Performance

Shares of Pharvaris stock opened at $27.56 on Thursday. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -8.18 and a beta of -2.58. The stock has a 50-day simple moving average of $27.07 and a 200-day simple moving average of $25.50. Pharvaris has a 52-week low of $11.51 and a 52-week high of $29.85.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors have recently made changes to their positions in the business. Tudor Investment Corp ET AL acquired a new stake in Pharvaris in the 3rd quarter valued at approximately $1,943,000. TFG Asset Management GP Ltd increased its position in Pharvaris by 48.1% in the 2nd quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company’s stock worth $3,311,000 after buying an additional 61,105 shares during the period. Boothbay Fund Management LLC lifted its holdings in shares of Pharvaris by 735.1% during the third quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company’s stock worth $3,373,000 after buying an additional 118,994 shares during the last quarter. General Atlantic L.P. boosted its position in shares of Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after acquiring an additional 500,000 shares during the period. Finally, Patient Square Capital LP boosted its position in shares of Pharvaris by 41.4% in the third quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock valued at $8,617,000 after acquiring an additional 101,098 shares during the period.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Wedbush raised its price target on PHVS to $42 and kept an “outperform” rating, implying roughly a 50%+ upside from the stock’s recent level — a clear catalyst for buying interest. Read More.
• Positive Sentiment: HC Wainwright published a long-term bullish forecast, projecting FY2030 EPS of $5.37 and maintaining a “Buy” rating with a $60 price target — reinforcing upside expectations well above current levels. Read More.
• Positive Sentiment: HC Wainwright also lifted multiple multi-year earnings estimates (FY2027–FY2029/FY2030) and nudged FY2026 expectations slightly higher overall, signaling analyst confidence in Pharvaris’ longer-term revenue/earnings trajectory. This supports higher price-target revisions by other firms. Read More.
• Neutral Sentiment: HC Wainwright made mixed near-term adjustments: modest downward tweaks to Q1 and Q2 2026 EPS (e.g., Q1 to ($0.83) from ($0.80), Q2 to ($0.89) from ($0.87)) while slightly raising Q3/Q4 and later-year estimates — a mixed signal for short-term results but not a reversal of the bullish long-term call. Read More.
• Negative Sentiment: Royal Bank of Canada issued a pessimistic forecast for PHVS, which could temper upside momentum or trigger short-term selling by more conservative investors. Read More.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.